Sana Biotechnology (NASDAQ:SANA) Stock Price Down 11.1% – Time to Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price fell 11.1% during trading on Thursday . The company traded as low as $3.15 and last traded at $3.1550. 2,231,136 shares traded hands during trading, a decline of 31% from the average daily volume of 3,229,869 shares. The stock had previously closed at $3.55.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SANA. Wall Street Zen upgraded Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Wedbush upped their target price on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research report on Monday, May 11th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Sana Biotechnology Stock Performance

The stock has a market cap of $876.61 million, a price-to-earnings ratio of -3.39 and a beta of 2.13. The business’s 50 day moving average is $3.27 and its 200 day moving average is $3.61.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. Research analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after acquiring an additional 1,517,474 shares in the last quarter. State Street Corp boosted its holdings in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after purchasing an additional 1,374,300 shares during the period. Geode Capital Management LLC grew its position in Sana Biotechnology by 20.3% during the fourth quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock valued at $16,763,000 after purchasing an additional 694,606 shares in the last quarter. Integral Health Asset Management LLC increased its stake in Sana Biotechnology by 50.0% in the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $12,210,000 after buying an additional 1,000,000 shares during the period. Finally, Bank of America Corp DE increased its stake in Sana Biotechnology by 148.4% in the 1st quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock valued at $8,487,000 after buying an additional 1,760,610 shares during the period. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.